DOP2022000288A - Derivados de quinoxalina como fármacos contra el cáncer - Google Patents
Derivados de quinoxalina como fármacos contra el cáncerInfo
- Publication number
- DOP2022000288A DOP2022000288A DO2022000288A DO2022000288A DOP2022000288A DO P2022000288 A DOP2022000288 A DO P2022000288A DO 2022000288 A DO2022000288 A DO 2022000288A DO 2022000288 A DO2022000288 A DO 2022000288A DO P2022000288 A DOP2022000288 A DO P2022000288A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- cancer drugs
- quinoxaline derivatives
- quinoxaline
- derivatives
- drugs
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063044095P | 2020-06-25 | 2020-06-25 | |
| US202063120351P | 2020-12-02 | 2020-12-02 | |
| PCT/EP2021/067304 WO2021260092A1 (en) | 2020-06-25 | 2021-06-24 | Quinoxaline derivatives as anti-cancer drugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2022000288A true DOP2022000288A (es) | 2023-01-15 |
Family
ID=76662494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2022000288A DOP2022000288A (es) | 2020-06-25 | 2022-12-14 | Derivados de quinoxalina como fármacos contra el cáncer |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US11795158B2 (https=) |
| EP (1) | EP4172152A1 (https=) |
| JP (1) | JP7769650B2 (https=) |
| KR (1) | KR20230026450A (https=) |
| CN (3) | CN115768760B (https=) |
| AU (1) | AU2021295423B2 (https=) |
| BR (1) | BR112022025435A2 (https=) |
| CA (1) | CA3186996A1 (https=) |
| CL (1) | CL2022003711A1 (https=) |
| CO (1) | CO2023000186A2 (https=) |
| CR (1) | CR20230024A (https=) |
| DO (1) | DOP2022000288A (https=) |
| EC (1) | ECSP23005059A (https=) |
| IL (1) | IL299123B2 (https=) |
| MX (1) | MX2022015435A (https=) |
| PE (1) | PE20231081A1 (https=) |
| SA (1) | SA522441701B1 (https=) |
| TW (1) | TW202218664A (https=) |
| UA (1) | UA130043C2 (https=) |
| UY (1) | UY39296A (https=) |
| WO (1) | WO2021260092A1 (https=) |
| ZA (1) | ZA202300924B (https=) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3999506T1 (sl) | 2019-07-19 | 2025-06-30 | Astrazeneca Ab | Zaviralci PARP1 |
| US11795158B2 (en) * | 2020-06-25 | 2023-10-24 | Astrazeneca Ab | Chemical compounds |
| US12280049B2 (en) * | 2020-08-04 | 2025-04-22 | Astrazeneca Ab | Methods of delaying pain progression and treating prostate cancer |
| US11591331B2 (en) | 2021-04-19 | 2023-02-28 | Xinthera, Inc. | PARP1 inhibitors and uses thereof |
| CN115702156A (zh) * | 2021-04-23 | 2023-02-14 | 南京明德新药研发有限公司 | 吡啶酰胺类化合物 |
| BR112023022496A2 (pt) | 2021-05-24 | 2024-01-16 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Composto heterocíclico contendo nitrogênio, método de preparação do mesmo, e aplicação do mesmo em medicamentos |
| BR112023024942A2 (pt) * | 2021-06-16 | 2024-02-15 | Repare Therapeutics Inc | Uso de inibidores de atr em combinação com inibidores de parp para tratamento de câncer |
| US20240366584A1 (en) | 2021-06-21 | 2024-11-07 | Tesaro, Inc. | Combination treatment of cancer with a parp inhibitor and a lipophilic statin |
| AU2022334408A1 (en) | 2021-08-27 | 2024-02-15 | Impact Therapeutics (Shanghai), Inc. | Substituted tricyclic compounds as parp inhibitors and use thereof |
| WO2023046034A1 (zh) * | 2021-09-22 | 2023-03-30 | 明慧医药（杭州）有限公司 | 一种含氮杂环化合物、其制备方法、其中间体及其应用 |
| WO2023046149A1 (zh) * | 2021-09-26 | 2023-03-30 | 张文燕 | 喹喔啉类化合物及其医药用途 |
| WO2023046158A1 (zh) * | 2021-09-26 | 2023-03-30 | 张文燕 | 氮杂喹啉酮类化合物及其医药用途 |
| WO2023051716A1 (zh) * | 2021-09-30 | 2023-04-06 | 海思科医药集团股份有限公司 | 杂芳基衍生物parp抑制剂及其用途 |
| EP4410791A4 (en) * | 2021-09-30 | 2025-10-22 | Xizang Haisco Pharmaceutical Co Ltd | BICYCLIC DERIVATIVE PARP INHIBITOR AND ITS USE |
| KR102867210B1 (ko) | 2021-10-01 | 2025-10-14 | 신테라, 인크. | 아제티딘 및 피롤리딘 parp1 저해제, 및 이의 용도 |
| US20250289800A1 (en) | 2021-11-19 | 2025-09-18 | Kangbaida (Sichuan) Biotechnology Co., Ltd. | Selective Parp1 Inhibitor And Application Thereof |
| EP4452256B1 (en) * | 2021-12-21 | 2025-12-10 | Astrazeneca AB | Methods of treating brain tumours and neuroblastomas |
| KR20240134366A (ko) * | 2022-01-13 | 2024-09-09 | 에이스랜드 테라퓨틱스 (홍콩) 리미티드 | 피페라진 고리 함유 유도체, 이의 약학적으로 허용 가능한 염, 이의 제조방법 및 용도 |
| CN118434725B (zh) * | 2022-01-20 | 2026-01-02 | 微境生物医药科技(上海)有限公司 | 吡啶酰胺类parp抑制剂、及其制备方法和医药用途 |
| CN120081844A (zh) | 2022-01-21 | 2025-06-03 | 新特拉有限公司 | Parp1抑制剂及其用途 |
| JP7794989B2 (ja) * | 2022-01-27 | 2026-01-06 | シンセラ， インコーポレイテッド | Ｐａｒｐ１阻害薬及びその使用 |
| WO2023146960A1 (en) * | 2022-01-28 | 2023-08-03 | Xinthera, Inc. | Parp1 inhibitors and uses thereof |
| CN116693501B (zh) * | 2022-02-10 | 2025-12-19 | 康百达（四川）生物医药科技有限公司 | 一种喹唑啉酮衍生物及其在医药上的应用 |
| AU2023235233A1 (en) | 2022-03-14 | 2024-09-12 | Slap Pharmaceuticals Llc | Multicyclic compounds |
| WO2023201338A1 (en) | 2022-04-15 | 2023-10-19 | Ideaya Biosciences, Inc. | Combination therapy comprising a mat2a inhibitor and a parp inhibitor |
| AU2023259236B2 (en) | 2022-04-28 | 2025-01-09 | Xinthera, Inc. | Tricyclic parp1 inhibitors and uses thereof |
| WO2023207284A1 (en) * | 2022-04-28 | 2023-11-02 | Ningbo Newbay Technology Development Co., Ltd | Piperazine derivatives as parp1 inhibitiors |
| JP7835895B2 (ja) * | 2022-05-07 | 2026-03-25 | サイブランチ セラピューティクス カンパニー リミテッド | Ｐａｒｐ１を選択的に阻害するフルオロキノキサリノン誘導体 |
| EP4534537A4 (en) | 2022-05-25 | 2025-12-10 | Xizang Haisco Pharmaceutical Co Ltd | BICYCLE-DERIVED PARP INHIBITOR AND ITS USE |
| US20250346573A1 (en) * | 2022-06-02 | 2025-11-13 | Chengdu Easton Biopharmaceuticals Co., Ltd. | Azaquinolinone derivative, preparation method therefor and use thereof |
| US20250352539A1 (en) | 2022-06-15 | 2025-11-20 | Astrazeneca Ab | Combination therapy for treating cancer |
| CN115919859B (zh) * | 2022-07-14 | 2024-01-05 | 四川海思科制药有限公司 | 一种杂芳基衍生物的药物组合物及其在医药上的应用 |
| CN117658983A (zh) * | 2022-09-01 | 2024-03-08 | 浙江文达医药科技有限公司 | 选择性parp1抑制剂 |
| CN118119629A (zh) * | 2022-09-30 | 2024-05-31 | 中国医药研究开发中心有限公司 | 含氮杂环类化合物及其医药用途 |
| US20240174669A1 (en) * | 2022-10-06 | 2024-05-30 | Xinthera, Inc. | Crystalline forms of a parp1 inhibitor |
| WO2024083218A1 (zh) * | 2022-10-20 | 2024-04-25 | 成都赜灵生物医药科技有限公司 | 取代四氢吡啶类化合物及其用途 |
| CN120035596A (zh) | 2022-11-23 | 2025-05-23 | 江苏恒瑞医药股份有限公司 | 一种含氮杂环类化合物的可药用盐、晶型及制备方法 |
| KR20250116727A (ko) | 2022-12-06 | 2025-08-01 | 아스트라제네카 아베 | Polq 저해제 |
| CN121358725A (zh) | 2023-06-14 | 2026-01-16 | 海思科医药集团股份有限公司 | 双环衍生物parp抑制剂及其用途 |
| WO2025067417A1 (zh) | 2023-09-28 | 2025-04-03 | 成都赜灵生物医药科技有限公司 | 并内酰胺环类化合物及其用途 |
| WO2025092973A1 (zh) * | 2023-11-03 | 2025-05-08 | 成都赜灵生物医药科技有限公司 | Parp1靶向化合物及其用途 |
| TW202535479A (zh) | 2023-12-05 | 2025-09-16 | 英商阿斯特捷利康英國股份有限公司 | 抗體藥物結合物與血腦屏障穿透性ｐａｒｐ１選擇性抑制劑之組合 |
| CN120398887A (zh) * | 2024-01-31 | 2025-08-01 | 西藏海思科制药有限公司 | 一种双环衍生物parp抑制剂的晶型及其制备方法和应用 |
| KR20250128449A (ko) | 2024-02-20 | 2025-08-28 | 주식회사 종근당 | Parp1 억제제로서의 화합물 및 이를 포함하는 약학적 조성물 |
| WO2025248117A1 (en) | 2024-05-31 | 2025-12-04 | Astrazeneca Ab | 6-aminopurine derivatives useful as polq inhibitors |
| TW202547478A (zh) | 2024-05-31 | 2025-12-16 | 瑞典商阿斯特捷利康公司 | Ｐｏｌｑ抑制劑 |
| WO2026028140A1 (en) | 2024-08-01 | 2026-02-05 | Chong Kun Dang Pharmaceutical Corp. | Compound as parp1 inhibitor and pharmaceutical composition comprising the same |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE198623T1 (de) | 1994-08-12 | 2001-01-15 | Myriad Genetics Inc | Verfahren zum nachweis von prädisposition von ovarial- und brustkrebs |
| ATE201445T1 (de) | 1994-08-12 | 2001-06-15 | Myriad Genetics Inc | Mutationen des mit 17q verbundenen ovarial- und brustkrebs empfindlichkeitsgens |
| WO2003007959A1 (en) * | 2001-07-16 | 2003-01-30 | Fujisawa Pharmaceutical Co., Ltd. | Quinoxaline derivatives which have parp inhibitory action |
| PL1633724T3 (pl) | 2003-03-12 | 2011-10-31 | Kudos Pharm Ltd | Pochodne ftalazynonu |
| JP2010507387A (ja) | 2006-10-25 | 2010-03-11 | クアーク・ファーマスーティカルス、インコーポレイテッド | 新規のｓｉＲＮＡおよびその使用方法 |
| ES2393326T3 (es) | 2006-12-18 | 2012-12-20 | Amgen, Inc | Compuestos basados en azaquinolona que presentan actividad inhibidora de prolil hidroxilasas, composiciones y usos de los mismos |
| JP2009196973A (ja) * | 2007-09-26 | 2009-09-03 | Santen Pharmaceut Co Ltd | キナゾリノン誘導体又はキノキサリン誘導体を有効成分として含有する後眼部疾患の予防又は治療剤 |
| US8404713B2 (en) * | 2007-10-26 | 2013-03-26 | Janssen Pharmaceutica Nv | Quinolinone derivatives as PARP inhibitors |
| CN102341394B (zh) | 2009-01-23 | 2015-04-15 | 武田药品工业株式会社 | 聚(adp-核糖)聚合酶(parp)抑制剂 |
| WO2014045101A1 (en) * | 2012-09-21 | 2014-03-27 | Cellzome Gmbh | Tetrazolo quinoxaline derivatives as tankyrase inhibitors |
| CA2895426A1 (en) * | 2012-12-20 | 2014-06-26 | Bayer Pharma Aktiengesellschaft | Bet-protein-inhibiting dihydroquinoxalinones |
| EP2972381A2 (en) | 2013-03-14 | 2016-01-20 | Galapagos NV | Molecular targets and compounds, and methods to identify the same, useful in the treatment of diseases associated with epithelial mesenchymal transition |
| TW202246503A (zh) | 2013-07-19 | 2022-12-01 | 美商百健Ｍａ公司 | 用於調節τ蛋白表現之組合物 |
| MX375707B (es) | 2015-06-09 | 2025-03-06 | Onconic Therapeutics Inc | Compuesto derivativo triciclico, metodo para prepararlo y composicion farmaceutica que comprende el mismo. |
| SI3999506T1 (sl) | 2019-07-19 | 2025-06-30 | Astrazeneca Ab | Zaviralci PARP1 |
| US11795158B2 (en) * | 2020-06-25 | 2023-10-24 | Astrazeneca Ab | Chemical compounds |
-
2021
- 2021-06-22 US US17/354,322 patent/US11795158B2/en active Active
- 2021-06-24 KR KR1020237001972A patent/KR20230026450A/ko active Pending
- 2021-06-24 CA CA3186996A patent/CA3186996A1/en active Pending
- 2021-06-24 JP JP2022579869A patent/JP7769650B2/ja active Active
- 2021-06-24 PE PE2022002989A patent/PE20231081A1/es unknown
- 2021-06-24 BR BR112022025435A patent/BR112022025435A2/pt unknown
- 2021-06-24 CN CN202180043057.8A patent/CN115768760B/zh active Active
- 2021-06-24 WO PCT/EP2021/067304 patent/WO2021260092A1/en not_active Ceased
- 2021-06-24 CN CN202610271871.XA patent/CN121873040A/zh active Pending
- 2021-06-24 EP EP21735690.6A patent/EP4172152A1/en active Pending
- 2021-06-24 CR CR20230024A patent/CR20230024A/es unknown
- 2021-06-24 MX MX2022015435A patent/MX2022015435A/es unknown
- 2021-06-24 IL IL299123A patent/IL299123B2/en unknown
- 2021-06-24 AU AU2021295423A patent/AU2021295423B2/en active Active
- 2021-06-24 CN CN202610271887.0A patent/CN121949283A/zh active Pending
- 2021-06-24 UA UAA202300158A patent/UA130043C2/uk unknown
- 2021-06-25 TW TW110123282A patent/TW202218664A/zh unknown
- 2021-06-25 UY UY0001039296A patent/UY39296A/es unknown
-
2022
- 2022-12-11 SA SA522441701A patent/SA522441701B1/ar unknown
- 2022-12-14 DO DO2022000288A patent/DOP2022000288A/es unknown
- 2022-12-22 CL CL2022003711A patent/CL2022003711A1/es unknown
-
2023
- 2023-01-10 CO CONC2023/0000186A patent/CO2023000186A2/es unknown
- 2023-01-20 ZA ZA2023/00924A patent/ZA202300924B/en unknown
- 2023-01-23 EC ECSENADI20235059A patent/ECSP23005059A/es unknown
- 2023-09-14 US US18/467,185 patent/US12421208B2/en active Active
-
2025
- 2025-08-12 US US19/297,723 patent/US20250368615A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL299123A (en) | 2023-02-01 |
| US20250368615A1 (en) | 2025-12-04 |
| IL299123B2 (en) | 2026-04-01 |
| US20240010631A1 (en) | 2024-01-11 |
| AU2021295423A1 (en) | 2023-02-16 |
| UY39296A (es) | 2021-12-31 |
| UA130043C2 (uk) | 2025-10-22 |
| SA522441701B1 (ar) | 2024-08-11 |
| US20220009901A1 (en) | 2022-01-13 |
| AU2021295423B2 (en) | 2024-05-02 |
| MX2022015435A (es) | 2023-02-09 |
| ECSP23005059A (es) | 2023-02-28 |
| EP4172152A1 (en) | 2023-05-03 |
| TW202218664A (zh) | 2022-05-16 |
| US11795158B2 (en) | 2023-10-24 |
| BR112022025435A2 (pt) | 2023-01-24 |
| WO2021260092A1 (en) | 2021-12-30 |
| PE20231081A1 (es) | 2023-07-17 |
| CN115768760A (zh) | 2023-03-07 |
| IL299123B1 (en) | 2025-12-01 |
| CL2022003711A1 (es) | 2023-06-23 |
| KR20230026450A (ko) | 2023-02-24 |
| CN121949283A (zh) | 2026-05-01 |
| US12421208B2 (en) | 2025-09-23 |
| JP7769650B2 (ja) | 2025-11-13 |
| ZA202300924B (en) | 2024-09-25 |
| CA3186996A1 (en) | 2021-12-30 |
| CR20230024A (es) | 2023-03-01 |
| JP2023532257A (ja) | 2023-07-27 |
| CN115768760B (zh) | 2026-03-27 |
| CN121873040A (zh) | 2026-04-17 |
| CO2023000186A2 (es) | 2023-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP23005059A (es) | Derivados de quinoxalina como fármacos contra el cáncer | |
| UY38793A (es) | Compuestos químicos | |
| CY1123649T1 (el) | Παραγωγα ιμιδαζολινης, μεθοδοι παρασκευης αυτων και εφαρμογες αυτων στην ιατρικη | |
| CO6511228A2 (es) | (heteroarilmetil)tiohidantoínas sustituidas como drogas anticáncer | |
| CO2020003714A2 (es) | Compuestos de piridina, pirazina, y triazina como inhibidores de shp2 alostéricos | |
| MX2023009011A (es) | Inhibidor de cdk. | |
| CO2018013978A2 (es) | Derivados de ácido borónico y usos terapéuticos de los mismos. | |
| CL2018001624A1 (es) | Antagonistas policíclicos del tlr7/8 y uso de los mismos en el tratamiento de trastornos inmunitarios | |
| BR112015012555A2 (pt) | derivados de benzimidazol como antagonistas de ep4 | |
| CR20110610A (es) | Nuevos derivados de pirimidina y sus usos en el tratamiento del cáncer y otras enfermedades | |
| MX2016014547A (es) | Compuestos para tratar atrofia muscular espinal. | |
| PE20151437A1 (es) | Moduladores de receptores nmda de espiro-lactama y sus usos | |
| UY29803A1 (es) | Derivados de adeninas, composiciones farmacéuticas conteniéndolos, procedimientos de preparación y aplicaciones | |
| CO6680667A2 (es) | Derivados ester de ácido borónico cíclico y sus usos terapéuticos | |
| MX2019002541A (es) | Derivados de pirimidina contra virus de la influenza. | |
| MX2020012058A (es) | Compuestos de triazolopirimidina y su uso en el tratamiento del cancer. | |
| NI201700052A (es) | Diamino-quinoleína 2,4 sustituida como nuevos agentes anticancerígenos | |
| UY31905A (es) | Derivados de benzoxazinona, procesos de preparación, composiciones farmacéuticas conteniéndolos y aplicaciones. | |
| CO6341625A2 (es) | Derivados de indol como agentes anticáncer | |
| MX2018006953A (es) | Compuestos de platino funcionalizados con monomaleimida para la terapia del cancer. | |
| BR112016001876A2 (pt) | composto de benzoxaborol tricíclico, método de preparação e uso do mesmo | |
| CR20220299A (es) | Derivados de becimidazol | |
| PL401345A1 (pl) | Pochodne kamptotecyny, sposób ich otrzymywania i zastosowanie | |
| MX2018015707A (es) | Derivados biciclicos de piridina, pirazina y pirimidina como inhibidores de pi3k beta. | |
| CL2017001941A1 (es) | Uso de una mezcla de polímeros de glucosa modificadas para reducir metastasis de tumor |